Optibrium demonstrates superior molecular docking method for small molecules and macrocycles
Surflex-Dock structure-based design method outperforms other molecular docking methods for predicting non-cognate ligand pose of macrocyclic compounds Results published Open Access in Journal of Computer-Aided Molecular Design
Optibrium appoints James Halle as Chief Commercial Officer
Key appointment brings extensive software commercial experience to drive global growth.
Optibrium demonstrates accelerated lead optimisation in complex agrochemical development
Optibrium’s QuanSA 3D-QSAR method uses an active learning approach to successfully and more efficiently identify a mimic of a macrocyclic natural product
Optibrium partners with FMC Corporation to transform agrochemical discovery
Optibrium’s AI-powered discovery platform Cerella™ chosen by FMC to accelerate its agrochemical discovery pipeline.
Optibrium launches a metabolism prediction software platform tailored to DMPK scientists
Semeta™ offers high sensitivity and superior precision for the prediction of Phase I and II metabolic routes, sites, products and liabilities in early drug discovery
Optibrium enables collaborative design in its StarDrop platform
The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking The software promotes collaboration within and across teams for more cohesive workflows
Optibrium’s quantum mechanics and machine learning methods predict routes of drug metabolism
Peer-reviewed study published in Xenobiotica describes an innovative new method that predicts the routes and products of Phase I and II metabolism with high sensitivity and greater precision than other approaches.
Optibrium introduces cloud-based version of StarDrop drug discovery platform
Cloud-based version of StarDrop retains all the functionality and interactivity of desktop version with improved accessibility and lower total cost of ownership for customers. Optibrium recently received ISO 27001 accreditation for its information security system.
Optibrium releases powerful metabolism prediction capability in next generation StarDrop software
Cambridge, UK – Optibrium, a leading developer of software and AI solutions for drug discovery, launches the latest version of its drug discovery platform, StarDrop 7.5, introducing a powerful module for drug metabolism prediction.
Optibrium acquires BioPharmics LLC, expanding its 3D drug design and visualisation offering
BioPharmics’ Drs Ajay Jain (CEO) and Ann Cleves (Director of Applied Science) join the Optibrium team as Vice Presidents in the newly-created BioPharmics Division.
Dr Hamed Tabatabaei Ghomi welcomed as Head of Research
Optibrium Appoints Computational Modelling Expert, Dr Hamed Tabatabaei Ghomi as Head of Research.
Optibrium and PostEra collaborate to integrate AI drug discovery solutions
The collaboration connects PostEra’s synthesis prediction technology with Optibrium’s comprehensive platform for design, optimisation and data analysis for small molecule discovery
Optibrium appoints Steve Yemm as Chief Commercial Officer
CAMBRIDGE, UK – Optibrium, a leading developer of software and AI solutions for drug discovery, announces the appointment of Steve Yemm as Chief Commercial Officer (CCO), the latest in a series of senior-level hires as the Company rapidly expands.
Optibrium appoints Ian Smith as Chief Technology Officer
As CTO, Ian will lead the Software Engineering, DevOps and Quality Assurance teams, driving the scale-up of the Company’s infrastructure and managing the expanding portfolio of products and development projects.
Optibrium and Lhasa Limited advance predictive modelling for drug-metabolising enzymes
Cambridge and Leeds – Optibrium and Lhasa Limited, two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and development, announces the publication of a peer-reviewed study in the Journal of Medicinal Chemistry.
Optibrium expands operations in North America for AI and computational drug discovery technologies
CAMBRIDGE, UK and CAMBRIDGE, US – Optibrium, a leading developer of software and artificial intelligence (AI) solutions for drug discovery, announces the opening of its US subsidiary, Optibrium Inc., and the promotion of Dr Tamsin Mansley to President of the new subsidiary to lead its US-based team and business operations.
Optibrium strengthens global AI drug discovery software operations with three key appointments
Cambridge, UK - Optibrium, a leading developer of software and artificial intelligence (AI) solutions for drug discovery, announces three key appointments: Michelle Harrison as Head of Strategic Marketing, Chris Khoury as Associate Director of Business Development, and Imran Ghauri as Business Development Manager.
Optibrium and Cresset announce technology collaboration
Optibrium, a provider of drug discovery software solutions, and software and services provider Cresset, announce an agreement to collaborate on the development of next-generation platforms, combining their unique approaches to help drug discovery projects quickly identify novel, potent compounds with a high chance of success.
Optibrium expands StarDrop availability with Apple Mac compatibility
CAMBRIDGE, UK, October 18, 2011 – Optibrium launches StarDrop 5.1, an upgraded version of its software platform that helps scientists to guide the design and selection of high quality, novel compounds in drug discovery. As a result of this upgrade, StarDrop’s unique capabilities to guide are now available on the Apple Mac.